Pfizer's financial results have been subpar in recent years. The company's newer products are starting to come into their own. The drugmaker's pipeline could lead to even more important brand-new ...
GLP-1 drugs have seen strong consumer demand. Eli Lilly's industry-leading GLP-1 drugs Mounjaro and Zepbound, for example, saw revenue growth of 99% and 175%, respectively, in 2025. The flameout of ...
The Motley Fool on MSN
Is Pfizer's 6% Dividend Yield Safe? Here's What Investors Need to Know.
Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.
Hosted on MSN
Pfizer stock: Still priced like it's dead money
Pfizer is facing headwinds today, which is why investors seem to be ignoring the stock. The giant pharmaceutical company is still an industry leader and a highly innovative competitor. 10 stocks we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results